Chromium urine levels may be used to monitor short term exposure. Preferred test for evaluating metal ion release from metal-on-metal joint arthroplasty is Chromium, Serum (0098830).
Quantitative Inductively Coupled Plasma-Mass Spectrometry
Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician). High concentrations of iodine may interfere with elemental testing. Collection of urine specimens from patients receiving iodinated or gadolinium-based contrast media should be avoided for a minimum of 72 hours post-exposure. Collections from patients with impaired kidney function should be avoided for a minimum of 14 days post contrast media exposure.
24-hour or random urine collection. Specimen must be collected in a plastic container. ARUP studies indicate that refrigeration of urine alone, during and after collection, preserves specimens adequately, if tested within 14 days of collection.
Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Urine collected within 72 hours after administration of iodinated or gadolinium-based contrast media. Acid preserved urine. Specimens contaminated with blood or fecal material. Specimens transported in non-trace element-free transport tube (with the exception of the original device).
Record total volume and collection time interval on transport tube and on test request form.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year
|Chromium, Urine - per volume||0.0-2.0 µg/L|
|Chromium, Urine - per 24h||0.0-2.0 µg/d|
|Chromium, Urine - ratio to CRT||0.0-10.0 (µg/g crt)|
|0020473||Creatinine, Urine - per 24h||
Chromium urine levels can be used to monitor short term exposure. The form of chromium greatly influences distribution. Trivalent chromium resides in the plasma and is usually not of clinical importance. Hexavalent chromium is considered highly toxic. Symptoms associated with chromium toxicity vary based upon route of exposure and dose and may include dermatitis, impairment of pulmonary function, gastroenteritis, hepatic necrosis, bleeding, and acute tubular necrosis.
The ACGIH Biological Exposure Index for daily exposure of hexavalent chromium is an increase of 10 µg/gCRT between pre-shift and post-shift urine collections. The ACGIH Biological Exposure Index for long- and short-term hexavalent chromium is an end-of-shift concentration of 30 µg/gCRT at the end of the work week.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0020207||Creatinine, Urine - per volume||2161-8|
|0020208||Creatinine, Urine - per 24h||2162-6|
|0025101||Chromium, Urine - per 24h||5624-2|
|0025102||Chromium, Urine - ratio to CRT||29919-8|
|0099463||Chromium, Urine - per volume||21201-9|
- Urine chromium concentration